Finding a new therapy for patients with glioblastoma
It’s a diagnosis that can devastate a patient – glioblastoma multiforme. It is an extremely aggressive brain tumor that is resistant to treatment. Radiotherapy, chemotherapy, even extensive attempts to remove the tumor surgically cannot force the cancer into remission, leaving physicians with few options. Treatment options for recurrent glioblastoma are limited and often have little benefit. Despite the emergence of intensive treatment strategies, the median survival of patients with glioblastoma is 16 months and only 3-5 per cent of patients survive longer than 3 years. The recurrence of the disease in the months following treatment is almost inevitable. Glioblastoma is a deadly disease, but researchers at the MUHC have uncovered a therapy that may change the prognosis for patients. Now, we need your help to make this unprecedented therapy available to all.
In response to the devastation of glioblastoma, Dr. Bassam Abdulkarim of the Research Institute of the McGill University Health Centre (RI-MUHC) put together a diverse team of physicians and researchers to discover new therapies for patients diagnosed with glioblastoma.
After ten years of research and development, the MUHC’s Cancer Therapeutics Research Team is proud to have discovered a promising new therapy, called ZR2002. The drug will soon be ready for clinical trials, the first step toward making it available to patients.
ZR2002 has performed well in preclinical testing, a positive step toward having it approved by federal drug regulators.
More importantly, it is able to cross the blood-brain barrier, a difficulty that proves fatal to most drug discoveries for glioblastoma. This natural barrier that protects the brain from infection also prevents lifesaving treatment
How you can help
The incredible success of ZR2002 in preclinical models is unmatched by any other cancer drug currently on the market.
In order to make it available to thousands of patients across Canada and the world, we need your help to bring this discovery from the laboratory to clinical research.
This important work will help physicians determine optimal treatment protocols when using ZR2002, giving patients the best possible chance at a positive outcome.
For more information, please contact, Edith Bolduc, Associate Director of Development at the MUHC Foundation.
T. 514-843-1543 x 34397 email@example.com